Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction

Gastroenterology

Volumn 133, Issue 1, 2007, Pages 80-90

  Richardson, Michelle M ^a   Jonsson, Julie R ^a   Powell, Elizabeth E ^a   Brunt, Elizabeth M ^b   Neuschwander Tetri, Brent A ^b   Bhathal, Prithi S ^c   Dixon, John B ^d   Weltman, Martin D ^e   Tilg, Herbert ^f   Moschen, Alexander R ^f   Purdie, David M ^g   Demetris, Anthony J ^h   Clouston, Andrew D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Saint Louis University   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e NEPEAN HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOPSY; CELL CYCLE ARREST; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL; LIVER FIBROSIS; LIVER HILUS; LIVER REGENERATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK; STEM CELL;

EID: 34447100647     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.05.012     Document Type: Article

References (57)

1. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
2. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., and Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
3. Schwimmer J.B., Behling C., Newbury R., Deutsch R., Nievergelt C., Schork N.J., and Lavine J.E. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 (2005) 641-649
4. Nobili V., Marcellini M., Devito R., Ciampalini P., Piemonte F., Comparcola D., Sartorelli M.R., and Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44 (2006) 458-465
5. Adler M., and Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67 (1979) 811-816
6. Roskams T., Yang S.Q., Koteish A., Durnez A., DeVos R., Huang X., Achten R., Verslype C., and Diehl A.M. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 163 (2003) 1301-1311
7. Yang S., Koteish A., Lin H., Huang J., Roskams T., Dawson V., and Diehl A.M. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 39 (2004) 403-411
8. Crary G.S., and Albrecht J.H. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 28 (1998) 738-743
9. Marshall A., Rushbrook S., Davies S.E., Morris L.S., Scott I.S., Vowler S.L., Coleman N., and Alexander G. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 128 (2005) 33-42
10. Wagayama H., Shiraki K., Yamanaka T., Sugimoto K., Ito T., Fujikawa K., Takase K., and Nakano T. p21WAF1/CTP1 expression and hepatitis virus type. Dig Dis Sci 46 (2001) 2074-2079
11. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 33 (2001) 738-770
12. Roskams T. Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus. J Hepatol 39 (2003) 431-434
13. Roskams T., De Vos R., Van Eyken P., Myazaki H., Van Damme B., and Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 29 (1998) 455-463
14. Roskams T.A., Theise N.D., Balabaud C., Bhagat G., Bhathal P.S., Bioulac-Sage P., Brunt E.M., Crawford J.M., Crosby H.A., Desmet V., Finegold M.J., Geller S.A., Gouw A.S., Hytiroglou P., Knisely A.S., Kojiro M., Lefkowitch J.H., Nakanuma Y., Olynyk J.K., Park Y.N., Portmann B., Saxena R., Scheuer P.J., Strain A.J., Thung S.N., Wanless I.R., and West A.B. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 39 (2004) 1739-1745
15. Grappone C., Pinzani M., Parola M., Pellegrini G., Caligiuri A., DeFranco R., Marra F., Herbst H., Alpini G., and Milani S. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 31 (1999) 100-109
16. Malizia G., Brunt E.M., Peters M.G., Rizzo A., Broekelmann T.J., and McDonald J.A. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology 108 (1995) 145-156
17. Ramm G.A., Nair V.G., Bridle K.R., Shepherd R.W., and Crawford D.H. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. Am J Pathol 153 (1998) 527-535
18. Milani S., Herbst H., Schuppan D., Stein H., and Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 139 (1991) 1221-1229
19. Pinzani M., Milani S., De Franco R., Grappone C., Caligiuri A., Gentilini A., Tosti-Guerra C., Maggi M., Failli P., Ruocco C., and Gentilini P. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110 (1996) 534-548
20. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., Romanelli R.G., Laffi G., and Gentilini P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152 (1998) 423-430
21. Sedlaczek N., Jia J.D., Bauer M., Herbst H., Ruehl M., Hahn E.G., and Schuppan D. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 158 (2001) 1239-1244
22. Yasoshima M., Kono N., Sugawara H., Katayanagi K., Harada K., and Nakanuma Y. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. Lab Invest 78 (1998) 89-100
23. Milani S., Herbst H., Schuppan D., Kim K.Y., Riecken E.O., and Stein H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 98 (1990) 175-184
24. Milani S., Herbst H., Schuppan D., Surrenti C., Riecken E.O., and Stein H. Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. Am J Pathol 137 (1990) 59-70
25. Herbst H., Frey A., Heinrichs O., Milani S., Bechstein W.O., Neuhaus P., and Schuppan D. Heterogeneity of liver cells expressing procollagen types I and IV in vivo. Histochem Cell Biol 107 (1997) 399-409
26. Paradis V., Dargere D., Vidaud M., De Gouville A.C., Huet S., Martinez V., Gauthier J.M., Ba N., Sobesky R., Ratziu V., and Bedossa P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30 (1999) 968-976
27. Clouston A.D., Powell E.E., Walsh M.J., Richardson M.M., Demetris A.J., and Jonsson J.R. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 41 (2005) 809-818
28. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
29. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
30. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
31. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R.N., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
32. Kinnman N., Francoz C., Barbu V., Wendum D., Rey C., Hultcrantz R., Poupon R., and Housset C. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83 (2003) 163-173
33. Kinnman N., Hultcrantz R., Barbu V., Rey C., Wendum D., Poupon R., and Housset C. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 80 (2000) 697-707
34. Kruglov E.A., Nathanson R.A., Nguyen T., and Dranoff J.A. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol 290 (2006) G765-G771
35. Xia J.L., Dai C., Michalopoulos G.K., and Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol 168 (2006) 1500-1512
36. Sicklick J.K., Choi S.S., Bustamante M., McCall S.J., Perez E.H., Huang J., Li Y.X., Rojkind M., and Diehl A.M. Evidence for epithelial-mesenchymal transitions in adult liver cells. Am J Physiol 291 (2006) G575-G583
37. Robertson H., Kirby J.A., Yip W.W., Jones D.E.J., and Burt A.D. Biliary epithelial cell to mesenchymal cell transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 45 (2007) 977-981
38. Kooby D.A., Fong Y., Suriawinata A., Gonen M., Allen P.J., Klimstra D.S., DeMatteo R.P., D'Angelica M., Blumgart L.H., and Jarnagin W.R. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
39. Picard C., Lambotte L., Starkel P., Sempoux C., Saliez A., Van den Berge V., and Horsmans Y. Steatosis is not sufficient to cause an impaired regenerative response after partial hepatectomy in rats. J Hepatol 36 (2002) 645-652
40. DeAngelis R.A., Markiewski M.M., Taub R., and Lambris J.D. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology 42 (2005) 1148-1157
41. Zhang B.H., Weltman M., and Farrell G.C. Does steatohepatitis impair liver regeneration?. A study in a dietary model of non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol 14 (1999) 133-137
42. Rao M.S., Papreddy K., Abecassis M., and Hashimoto T. Regeneration of liver with marked fatty change following partial hepatectomy in rats. Dig Dis Sci 46 (2001) 1821-1826
43. Torbenson M., Yang S.Q., Liu H.Z., Huang J., Gage W., and Diehl A.M. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol 161 (2002) 155-161
44. Yang S.Q., Lin H.Z., Mandal A.K., Huang J., and Diehl A.M. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 34 (2001) 694-706
45. Selzner M., and Clavien P.A. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 31 (2000) 35-42
46. Rudnick D.A. Trimming the fat from liver regeneration. Hepatology 42 (2005) 1001-1003
47. Farrell G.C., Robertson G.R., Leclercq I., and Horsmans Y. Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease?. Hepatology 35 (2002) 731-732
48. Leclercq I.A., Field J., and Farrell G.C. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology 124 (2003) 1451-1464
49. Colombat M., Charlotte F., Ratziu V., and Poynard T. Portal lymphocytic infiltrate in alcoholic liver disease. Hum Pathol 33 (2002) 1170-1174
50. Kofman A.V., Morgan G., Kirschenbaum A., Osbeck J., Hussain M., Swenson S., and Theise N.D. Dose- and time-dependent oval cell reaction in acetaminophen-induced murine liver injury. Hepatology 41 (2005) 1252-1261
51. Lowes K.N., Brennan B.A., Yeoh G.C., and Olynyk J.K. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 154 (1999) 537-541
52. Eleazar J.A., Memeo L., Jhang J.S., Mansukhani M.M., Chin S., Park S.M., Lefkowitch J.H., and Bhagat G. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol 41 (2004) 983-991
53. Libbrecht L., Desmet V., Van Damme B., and Roskams T. Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: can 'progenitor cells' migrate?. J Pathol 192 (2000) 373-378
54. Fotiadu A., Tzioufa V., Vrettou E., Koufogiannis D., Papadimitriou C.S., and Hytiroglou P. Progenitor cell activation in chronic viral hepatitis. Liver Int 24 (2004) 268-274
55. Ray M.B., Mendenhall C.L., French S.W., Gartside P.S., and The Veterans Administration Cooperative Study Group. Bile duct changes in alcoholic liver disease. Liver 13 (1993) 36-45
56. Lunz III J.G., Tsuji H., Nozaki I., Murase N., and Demetris A.J. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 41 (2005) 1262-1271
57. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 42 (2005) 5-13